Premium
The role of antiviral and immunoglobulin therapy in the prevention of Epstein–Barr virus infection and post‐transplant lymphoproliferative disease following solid organ transplantation
Author(s) -
Green Michael,
Reyes Jorge,
Webber Steven,
Rowe David
Publication year - 2001
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1034/j.1399-3062.2001.003002097.x
Subject(s) - medicine , ganciclovir , chemoprophylaxis , immunology , transplantation , organ transplantation , disease , virus , clinical trial , epstein–barr virus , lymphoproliferative disease , aciclovir , antibody , lymphoproliferative disorders , epstein–barr virus infection , herpesviridae , viral disease , lymphoma , human cytomegalovirus
The recognition of the importance of Epstein–Barr virus (EBV) infection, including EBV‐associated post‐transplant lymphoproliferative disease (PTLD), has led to a new focus on the prevention of this problem. This paper reviews the scientific rationale behind, and clinical experience with, the use of chemoprophylaxis (using acyclovir or ganciclovir) and immunoprophylaxis (using intravenous immunoglobulin) in the prevention of EBV/PTLD. While some centers have already introduced the use of one or both of these agents as standard prophylaxis against the development of this complication, published data in support of these protocols are currently lacking. Well designed clinical trials are necessary to evaluate the potential role of both antiviral and immunoglobulin agents in the prevention of EBV/PTLD in organ transplant recipients.